It is the sense of the Congress that (1) in developing, updating, and implementing the guidelines under section 498E of the Public Health Service Act, as added by section 3, the Director of the National Institutes of Health should consult with the Commissioner of Food and Drugs; (2) any research using human stem cells, irrespective of whether such research is federally funded, should comply with the guidelines under section 498E; and (3) the Commissioner of Food and Drugs should keep the Director of the National Institutes of Health informed of the types of human stem cell and related research that would facilitate the evaluation of the safety or effectiveness of drugs, devices, and biological products. In developing and updating the guidelines under this section, the Director of NIH shall, as appropriate, take into consideration guidelines on human stem cell research developed by nationally and internationallyrecognized scientific organizations. The Director of NIH shall determine the extent to which the guidelines under this section shall apply to research described in paragraph (1) that uses human stem cells derived before the effective date of such guidelines. Not later than 90 days after the date of the enactment of this section, the Director of NIH (1) shall issue guidelines on research involving human embryonic stem cells; and (2) may issue guidelines on research involving other human stem cells, as determined to be scientifically warranted by the Director of NIH. SECTION 1. SHORT TITLE. This Act may be cited as the Stem Cell Research Enhancement Act of 2008.